On 29 July 2004, orphan designation (EU/3/04/207) was granted by the European Commission to Bayer Healthcare AG, Germany, for sorafenib tosylate for the treatment of renal cell carcinoma.
The sponsorship was transferred to Bayer Shering Pharma AG, Germany, in April 2009. Bayer Shering Pharma AG changed its name to Bayer Pharma AG in October 2011.
Update: sorafenib tosylate for treatment of renal cell carcinoma has been authorised in the EU as Nexavar since 19 July 2006.
|Disease / condition||
Treatment of renal-cell carcinoma
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;